Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1533257
This article is part of the Research Topic Multi-omics Application in Exploring Potential Biomarkers Targeting Resistance of Anti-Cancer Drugs, Volume II View all articles

ASF1B Promotes Gastric Cancer Progression by Modulating H2AC20 and Activating PI3K/AKT and ERK1/2 Pathways

Provisionally accepted
Mengyuan Zhao Mengyuan Zhao 1Junchang Zhang Junchang Zhang 2Yanjun He Yanjun He 1Chongge You Chongge You 1*
  • 1 Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China
  • 2 Department of Anesthesiology, Shandong Provincial Hospital, Jinan, Shandong Province, China

The final, formatted version of the article will be published soon.

    Gastric cancer (GC) ranks among the most prevalent malignant neoplasms globally and is associated with a significant mortality rate. Despite the availability of various therapeutic interventions for GC, the overall prognosis for this disease remains unfavorable. This can be attributed to several factors, including delayed diagnosis and the inherent heterogeneity of the tumors. With the continuous enrichment of treatment methods, GC has entered an era of comprehensive treatment oriented toward precision and standardization. Through the application of bioinformatics and assessments of tissue microarrays, this study has selected the histone chaperone Anti-Silencing Function 1B (ASF1B) for detailed analysis. The analysis, in conjunction with clinical specimens, demonstrated that ASF1B is significantly upregulated in GC tissues and correlates with unfavorable prognostic outcomes. We then constructed ASF1B knockout and overexpression cell lines, and conducted biological function tests on this basis, proving that ASF1B contributes to tumor cell proliferation, colony formation, invasion and migration, and plays an important role in the progression of GC in vivo. These findings were validated at both the mouse and organoid levels. Additionally, human immune reconstitution was performed in NOD-PrkdcscidIl2rgem1/Smoc (NSG) mice, followed by flow cytometry analysis of mouse blood. We observed that ASF1B is involved in the tumor microenvironment, where ASF1B knockdown increases CD8+ T cell infiltration, indicating a negative correlation with immune activation. Mechanically, proteinprotein interaction analyses were conducted utilizing Immunoprecipitation-Mass Spectrometry (IP-MS) and Tandem mass tagging (TMT) methodologies to identify protein clusters. Our investigation revealed that ASF1B emerged as a promoter of GC progression by downregulating H2A clustered histone 20 (H2AC20), thereby influencing the activation of the phosphoinositide 3-kinase (PI3K) / protein kinase B (AKT)and extracellular regulated protein kinases (ERK)1/2 signaling pathways. Consequently, ASF1B, recognized as an oncogene, contributes to the initiation and progression of tumors, positioning it as a prospective target for therapeutic intervention in GC.

    Keywords: gastric cancer, AFS1B, H2AC20, PI3K/AKT, ERK1/2

    Received: 23 Nov 2024; Accepted: 24 Jan 2025.

    Copyright: © 2025 Zhao, Zhang, He and You. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chongge You, Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.